Division of Pulmonary/Critical Care Medicine, the Oklahoma City VA Medical Center and the University of Oklahoma Health Sciences Center, 920 Stanton L. Young Boulevard, WP 1310, Oklahoma City, OK 73104-5020, USA.
Biomed Res Int. 2013;2013:498205. doi: 10.1155/2013/498205. Epub 2013 Aug 18.
Improvement in PFT after bronchodilators is characteristic of obstructive airway diseases such as COPD. However, improvement in patients with restrictive pattern is occasionally seen. We aim to determine the clinical significance of a bronchodilator responsive restrictive defect.
Patients with restrictive spirometry and a bronchodilator study were identified at the University of Oklahoma and Oklahoma City VAMC between September 2003 and December 2009. Restriction was defined as a decreased FVC and FEV1, with normal FEV1/FVC. Responsiveness to bronchodilators was defined as an improvement in FEV1 and/or FVC of at least 12% and 200 mL. Patients with lung volume measurements had their clinical and radiographic records reviewed.
Twenty-one patients were included in the study. Most were current or ex-smokers, with most being on bronchodilators. The average FVC and FEV1 were 65 ± 11% and 62 ± 10% of the predicted, respectively. Most patients (66%) had a normal TLC, averaging 90 ± 16% of the predicted. RV, RV/TLC, and the TLC-VA values strongly suggested an obstructive defect.
Reversible restrictive pattern on spirometry appears to be a variant of obstructive lung disease in which early airway closure results in air trapping and low FVC. In symptomatic patients, a therapeutic trial of bronchodilators may be beneficial.
支气管扩张剂后 PFT 的改善是 COPD 等阻塞性气道疾病的特征。然而,限制性模式的患者偶尔也会出现改善。我们旨在确定支气管扩张剂反应性限制缺陷的临床意义。
2003 年 9 月至 2009 年 12 月,在俄克拉荷马大学和俄克拉荷马城退伍军人事务医疗中心确定了具有限制性肺量计和支气管扩张剂研究的患者。限制定义为 FVC 和 FEV1 降低,FEV1/FVC 正常。支气管扩张剂的反应性定义为 FEV1 和/或 FVC 至少改善 12%和 200 mL。对进行了肺量测量的患者,回顾了其临床和影像学记录。
研究纳入了 21 名患者。大多数是当前或曾经吸烟者,大多数正在使用支气管扩张剂。平均 FVC 和 FEV1 分别为预测值的 65 ± 11%和 62 ± 10%。大多数患者(66%)TLC 正常,平均为预测值的 90 ± 16%。RV、RV/TLC 和 TLC-VA 值强烈提示存在阻塞性缺陷。
肺量计上可逆的限制性模式似乎是一种阻塞性肺疾病的变体,其中早期气道关闭导致空气滞留和 FVC 降低。在有症状的患者中,支气管扩张剂的治疗试验可能是有益的。